Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 73

Similar articles for PubMed (Select 16083337)

1.

New targets for neuropathic pain therapeutics.

Kinloch RA, Cox PJ.

Expert Opin Ther Targets. 2005 Aug;9(4):685-98. Review.

PMID:
16083337
2.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
3.

The ERK/MAPK pathway, as a target for the treatment of neuropathic pain.

Ma W, Quirion R.

Expert Opin Ther Targets. 2005 Aug;9(4):699-713. Review.

PMID:
16083338
4.

An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy.

Zin CS, Nissen LM, Smith MT, O'Callaghan JP, Moore BJ.

CNS Drugs. 2008;22(5):417-42. Review.

PMID:
18399710
5.

Neurotrophic factors as novel therapeutics for neuropathic pain.

Sah DW, Ossipo MH, Porreca F.

Nat Rev Drug Discov. 2003 Jun;2(6):460-72. Review.

PMID:
12776221
6.

Management of neuropathic pain.

Jensen TS, Finnerup NB.

Curr Opin Support Palliat Care. 2007 Aug;1(2):126-31. doi: 10.1097/SPC.0b013e3282eeb45f. Review.

PMID:
18685353
7.

Guidelines for the pharmacological treatment of peripheral neuropathic pain: expert panel recommendations for the middle East region.

Bohlega S, Alsaadi T, Amir A, Hosny H, Karawagh AM, Moulin D, Riachi N, Salti A, Shelbaya S.

J Int Med Res. 2010 Mar-Apr;38(2):295-317.

PMID:
20515552
8.

[New aspects in pain research at Bayer].

Nopper R, Gebert I.

Fortschr Neurol Psychiatr. 2003 Dec;71(12):683-9. German.

PMID:
14661162
9.

Emerging trends in the pharmacotherapy of chronic pain.

Nitu AN, Wallihan R, Skljarevski V, Ramadan NM.

Expert Opin Investig Drugs. 2003 Apr;12(4):545-59. Review.

PMID:
12665411
10.

Recent advances in the pharmacological management of pain.

Guindon J, Walczak JS, Beaulieu P.

Drugs. 2007;67(15):2121-33. Review.

PMID:
17927280
11.

Cannabinoids for the treatment of neuropathic pain: clinical evidence.

Ashton JC, Milligan ED.

Curr Opin Investig Drugs. 2008 Jan;9(1):65-75. Review.

PMID:
18183533
12.

Topical analgesics in neuropathic pain.

Sawynok J.

Curr Pharm Des. 2005;11(23):2995-3004. Review.

PMID:
16178758
13.

Use of anticonvulsants drugs for neuropathic painful conditions.

Hussain AM, Afshan G.

J Pak Med Assoc. 2008 Dec;58(12):690-6. Review.

PMID:
19157324
14.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
15.

Pregabalin: new drug. Very similar to gabapentin.

[No authors listed]

Prescrire Int. 2005 Dec;14(80):203-6.

PMID:
16397976
16.

Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline.

Chou R, Huffman LH; American Pain Society; American College of Physicians.

Ann Intern Med. 2007 Oct 2;147(7):505-14. Review. Erratum in: Ann Intern Med. 2008 Feb 5;148(3):247-8.

PMID:
17909211
17.

EFNS guidelines on pharmacological treatment of neuropathic pain.

Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P; EFNS Task Force.

Eur J Neurol. 2006 Nov;13(11):1153-69.

PMID:
17038030
18.

Adjuvant analgesics.

Knotkova H, Pappagallo M.

Med Clin North Am. 2007 Jan;91(1):113-24.

PMID:
17164107
19.

Mechanism-based treatment in chronic neuropathic pain: the role of antidepressants.

Coluzzi F, Mattia C.

Curr Pharm Des. 2005;11(23):2945-60. Review.

PMID:
16178755
20.

Update on gabapentin therapy of neuropathic pain.

Guay DR.

Consult Pharm. 2003 Feb;18(2):158-70, 173-8.

PMID:
16563056
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk